Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;15(6):5517-5522.
doi: 10.3892/etm.2018.6076. Epub 2018 Apr 17.

Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease

Hong Pan  1 , Ying Zhao  1 , Zhengping Zhai  2 , Jinyu Zheng  3 , Yong Zhou  1 , Qijin Zhai  1 , Xiangyang Cao  1 , Jisha Tian  1 , Liandong Zhao  1
Affiliations

Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease

Hong Pan et al. Exp Ther Med. 2018 Jun.

Abstract

Parkinson's disease is a neurodegenerative disease that frequently results in memory disorders, cognitive decline and dementia. Previous studies have reported that plasminogen activator inhibitor-1 (PAI-1) serves an important role in cardiovascular disease risk, adiposity, insulin resistance and inflammation. However, the role of PAI-1 in diagnosis and prognosis of patients with Parkinson's disease following deep brain stimulation (DBS) has not reported, to the best of our knowledge. Therefore, the purpose of the present study was to investigate the clinical significance of PAI-1 in patients with Parkinson's disease. Plasma PAI-1 levels were measured in 102 patients with Parkinson's disease who underwent DBS. It was demonstrated that plasma PAI-1 levels were significantly increased in patients with Parkinson's disease compared with healthy individuals (P<0.01). Patients with Parkinson's disease received DBS presented significantly improved cognitive competence compared with controls (P<0.01). DBS significantly decreased plasma PAI-1 levels in patients with Parkinson's disease compared with controls (P<0.05). It was also observed that plasma PAI-1 levels were significantly negatively associated with cognitive function for patients with Parkinson's disease (P<0.01). In conclusion, these findings demonstrated that the degree of Parkinson's disease severity is positively associated with circulating levels of plasma PAI-1 levels, which suggests that PAI-1 may be a potential diagnostic and prognostic marker for patients with Parkinson's disease.

Keywords: Parkinson's disease; cognitive competence; deep brain stimulation; plasminogen activator inhibitor-1.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plasma PAI-1 levels in patients with Parkinson's disease and healthy individuals. **P<0.01. PAI-1, plasminogen activator inhibitor-1.
Figure 2.
Figure 2.
DBS significantly improves cognitive competence for patients with Parkinson's disease compared with control, as determined by MoCA. **P<0.01. DBS, deep brain stimulation; MoCA, Montreal cognitive assessment.
Figure 3.
Figure 3.
Deep brain stimulation treatment markedly decreases plasma PAI-1 levels in patients with Parkinson's disease. *P<0.05, **P<0.01. PAI-1, plasminogen activator inhibitor-1; DBS, deep brain stimulation.
Figure 4.
Figure 4.
DBS treatment relieves the degree of anxiety for patients with Parkinson's disease compared with control group. *P<0.05, **P<0.01. DBS, deep brain stimulation.
Figure 5.
Figure 5.
Discrimination index is significantly improved by the treatment of deep brain stimulation for patients with Parkinson's disease. *P<0.05, **P<0.01. DBS, deep brain stimulation.
Figure 6.
Figure 6.
Plasma levels of PAI-1 are positively associated with the degree of clinical stage of Parkinson's disease. **P<0.01. PAI-1, plasminogen activator inhibitor-1.
Figure 7.
Figure 7.
Plasma PAI-1 levels are decreased during the treatment of Parkinson's disease. **P<0.01. PAI-1, plasminogen activator inhibitor-1.
Figure 8.
Figure 8.
Plasma PAI-1 levels are negatively associated with cognitive function for patients with Parkinson's disease. **P<0.01. PAI-1, plasminogen activator inhibitor-1; MoCA, Montreal cognitive assessment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mano T, Britton Z, Britton T. Anatomo-functional basis of nonmotor symptoms in Parkinson disease. Neurology. 2016;87:2506–2507. doi: 10.1212/WNL.0000000000003443. - DOI - PubMed
    1. Meles SK, Teune LK, de Jong BM, Dierckx RA, Leenders KL. Metabolic Imaging in Parkinson disease. J Nuclear Med. 2017;58:23–28. doi: 10.2967/jnumed.116.183152. - DOI - PubMed
    1. Cooper CA, Chahine LM. Biomarkers in prodromal Parkinson disease: A qualitative review. J Int Neuropsychol Soc. 2016;22:956–967. doi: 10.1017/S1355617716000503. - DOI - PubMed
    1. Chiou SM, Lin YC, Lu MK, Tsai CH. Bilateral subthalamic stimulation for advanced Parkinson disease: Early experience at an Eastern center. Neurol Sci. 2015;36:515–520. doi: 10.1007/s10072-014-2008-x. - DOI - PubMed
    1. Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014;20:2243–2249. doi: 10.12659/MSM.890861. - DOI - PMC - PubMed